The European Commission (EC) has granted marketing authorisation for Revolution Medicines’ Rasonque (daraxonrasib) to treat adult patients with metastatic pancreatic adenocarcinoma who have undergone at least one systemic therapy earlier.
Market authorisation for the pancreatic cancer drug in Europe follows approval in the US earlier this year. Credit: Explode/Shutterstock.com.
Subscribe to our email newsletter
The decision permits use of the once-daily oral tablet in individuals with or without an identified RAS tumour mutation.
Rasonque is a RAS(ON) multi-selective, noncovalent, tri-complex inhibitor.
The marketing authorisation applies to all European Union (EU) member states and the European Economic Area (EEA) nations Liechtenstein, Iceland, and Norway.
It does not cover Switzerland or the UK, both of which maintain independent regulatory frameworks.
Patient availability will vary by jurisdiction, depending on the completion of national pricing, health-technology assessment, and procedures related to reimbursement.
Revolution Medicines CEO and chairman Mark Goldsmith said: “Today’s European Commission approval of Rasonque represents a pivotal moment for people in the European Union living with metastatic pancreatic cancer, as well as their families.
“With Rasonque now approved, we are actively working with healthcare systems and stakeholders across the region to support timely access for eligible patients.
“We also continue to engage with regulatory authorities around the world with the goal of expanding and accelerating the reach of rasonque to patients who may benefit from it.”
The approval follows a positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The assessment took place under an expedited phased review within the EMA’s Cancer Medicines Pathfinder project, reflecting the therapy’s potential to address high unmet medical need.
The EC authorisation was underpinned by data from the global Phase III RASolute 302 registrational trial (NCT06625320), published in The New England Journal of Medicine and presented at the 2026 American Society of Clinical Oncology Annual Meeting.
RASolute 302 compared a daily 300mg dose of rasonque monotherapy against an investigator’s choice of four cytotoxic chemotherapy regimens in previously treated patients.
The study met all primary and key secondary endpoints in both the overall intent-to-treat (ITT) group and patients harbouring RAS G12 mutations.
Rasonque holds approval from the US Food and Drug Administration (FDA) for adults with metastatic disease who have received prior systemic therapy or cannot receive multiagent regimens.
Revolution Medicines is also evaluating it in global Phase III registrational trials for metastatic RAS-mutant non-small cell lung cancer and pancreatic cancer.
In August this year, BeOne Medicines signed a multi-part collaboration with Revolution Medicines to develop and commercialise targeted oncology therapies.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.